{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:14:59Z","timestamp":1787537699396,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL) patients face poor prognosis and limited therapies. The mTOR inhibitor everolimus and gemcitabine show modest efficacy as single agents in R\/R PTCL, warranting investigation of combination regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study conducted a single-center retrospective analysis of 24 patients diagnosed with peripheral T-cell lymphoma, aged 18 to 70 years, who experienced relapse or refractory disease following at least one first-line chemotherapy regimen, and received treatment at Guangdong Provincial People\u2019s Hospital between December 2017 and March 2021. CellTiter Glo and AnnexinV FITC\/PI assays evaluated cell viability and apoptosis\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The combination showed significant efficacy: objective response rate (ORR) 70.8%, complete response (CR) rate 45.8%, median time to response 1.7 months. With median follow-up of 22.3 months (95% CI 5.7\u201339.0), median progression-free survival (PFS) was 9.9 months (95% CI 0\u201320.81), and median duration of response (DOR) 16.8 months. Patients with CR\/partial response (PR) had longer PFS (18.7 vs. 1.2 months,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0007) and overall survival (OS) (30.9 vs. 5.8 months,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.021) than those with stable\/progressive disease. RNA-seq results showed that the combined therapeutic approach synergistically reduces cell viability and promotes apoptosis through the inhibition of the MYC signaling pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Everolimus-gemcitabine combination exhibits synergistic antitumor activity, offering a potential therapeutic strategy for R\/R PTCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1683550","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:28:22Z","timestamp":1764311302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed\/refractory peripheral T cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Ling","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanguo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-Label, phase II study of romidepsin in relapsed or refractory peripheral T-Cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma","volume":"189","author":"Huang","year":"2020","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1140","article-title":"Biphasic rapamycin effects in lymphoma and carcinoma treatment","volume":"77","author":"Liu","year":"2017","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470","article-title":"Morrow SN et\u00a0al: Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.canlet.2010.07.005","article-title":"Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma","volume":"298","author":"Chiang","year":"2010","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.6.368","article-title":"Staging non-Hodgkin lymphoma","volume":"55","author":"Armitage","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0707-5","article-title":"Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma","volume":"92","author":"Tobinai","year":"2010","journal-title":"Int J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.611690","article-title":"The role of mTOR inhibitors in hematologic disease: from bench to bedside","volume":"10","author":"Feng","year":"2020","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1593\/tlo.09277","article-title":"Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals","volume":"3","author":"O\u2019Reilly","year":"2010","journal-title":"Transl Oncol"},{"key":"B23","article-title":"The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma","volume":"35","author":"Hong","year":"2015","journal-title":"Anticancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0043","article-title":"Determinants of rapamycin sensitivity in breast cancer cells","volume":"10","author":"Noh","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143768","article-title":"C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas","volume":"101","author":"Manso","year":"2016","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2020_5833","article-title":"The clinicopathological characteristics of C-MYC protein in angioimmunoblastic T-cell lymphoma","volume":"69","author":"Peng","year":"2022","journal-title":"Acta Biochim Polonica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03691-7","article-title":"Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma","volume":"148","author":"Chen","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103","article-title":"Belch A et\u00a0al: Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8582","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: Phase I results","volume":"32","author":"Lunning","year":"2014","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Kumar SG et\u00a0al: Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143252","article-title":"A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Moon JH et\u00a0al: Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/bjh.12488","article-title":"A phase I\/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas","volume":"163","author":"Evens","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:28:24Z","timestamp":1764311304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1683550"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1683550","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1683550"}}